Catalog No.: PC-38422Not For Human Use, Lab Use Only.
DRP-104 (Sirpiglenastat) is a novel broad acting glutamine antagonist, has significant anticancer activity by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.
DRP-104 (Sirpiglenastat) is a novel broad acting glutamine antagonist, has significant anticancer activity by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.
DRP-104 (Sirpiglenastat) has significant single agent activity in various tumor types, including KEAP1 and STK11 mutant non-small cell lung cancers (NSCLC), osimertinib resistant NSCLC as well as PIK3CA/PTEN mutant head and neck squamous cell carcinoma (SCCHN).
DRP-104 mediated tumor growth inhibition (TGI) is associated with increased tumor-infiltrating leukocytes (TIL) including T, NKT, and NK cells; M1-polarized tumor associated macrophages; and decreased immune-suppressive cells such as MDSCs.
